Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069231 | 0.93 | PPARG (0.39) | SLC1A5HTTSMN1; SMN2FAAHPPARA | |
| SCHEMBL7070132 | 0.86 | KMT2A (0.49) | KMT2AALOX5APFAAHPPARAPPARG | |
| SCHEMBL7069255 | 0.82 | MME (0.39) | KMT2AHTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL7068767 | 0.82 | PPARA (0.58) | PPARAPPARG | |
| SCHEMBL7604848 | 0.81 | MGAM (0.43) | SLC1A5HTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL7066053 | 0.81 | FFAR4 (0.38) | HTTSMN1; SMN2FAAHPTGER1 | |
| SCHEMBL7065979 | 0.81 | MME (0.42) | KMT2ASLC1A5HTTSMN1; SMN2FAAH | |
| SCHEMBL7067687 | 0.80 | MGAM (0.41) | SLC1A5HTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL7069229 | 0.78 | PPARG (0.52) | KMT2AALOX5APPPARAPPARG | |
| SCHEMBL7066080 | 0.78 | SMN1; SMN2 (0.41) | KMT2AHTTLMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | KMT2A 2329/4885SLC1A5 2360/4885HTT 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.